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In the current era, endovascular repair is preferred when feasible, but it involves its own set of potential complications and should not be performed until a large AAAs has evolved. 10 This increase in the detection of smaller AAAs highlights a number of opportunities for improving prevention, diagnosis, delaying progression, and managing this condition. Hence, additional biomarkers would aid in enhancing the accuracy of early diagnosis and appropriate tailored interventions that may delay the development of large AAAs which, in turn, would require intervention. Such an initiative may decrease morbidity and mortality.
Lipoprotein(a) (Lp(a)) is a cholesterol and oxidized phospholipid rich particle that is composed of apolipoprotein B-100 covalently linked via a disulfide bond to apolipoprotein (a) (apo(a)). 11, 12 High plasma levels of Lp(a) are strongly associated with coronary artery disease, stroke, and peripheral artery disease. [13] [14] [15] The LDL-like component of Lp(a) promotes atherosclerosis and the plasminogen-like apo(a) particle promotes both inflammation via its oxidized phospholipid content 16, 17 and potentially thrombosis by interfering with fibrinolysis. 18 Lipoprotein(a) has a potent lysine-binding site that allows strong affinity for vessel wall fibrin and proteoglycans and is identified in high amounts in atherosclerotic plaques of the human aorta. 19, 20 In this issue of Angiology, Kotani et al 21 conducted an updated meta-analysis of studies that evaluated Lp(a) levels and their association with AAA. The search identified 9 eligible studies (mainly case-control studies) published between 1988 and 2013 that included 1,564 patients with AAA. The authors appropriately did not add 2 studies of acute AAA rupture. Effect sizes were expressed as standardized mean difference (SMD) and 95% confidence interval (CI) due to different assays to determine Lp(a) levels, and therefore, an easily interpretable measure of clinical risk, such as an odds ratio, is not available. The analysis showed that patients with AAA had modest but significantly higher levels of Lp(a) compared to controls (SMD: 0.87, 95% CI: 0.41-1.33, P < .001), allowing the authors to conclude that circulating Lp(a) may be a useful biomarker in screening for the presence of AAA. This metaanalysis expands by 584 cases the results of a prior analysis that fundamentally shows similar results. 22 This earlier study included 5 case-control studies with 982 cases with AAA and 1,296 controls, showing significantly higher Lp(a) levels in the AAA group than those in the control group in random-effect models (SMD: 0.26, 95% CI: 0.08-0.44, P ¼ .005).
The current meta-analysis has several limitations inherent in both the methodology of case-control studies and metaanalyses, as well as in the biology of Lp(a). Regarding methodology, both the definition of AAA and the methods of Lp(a) measurements were different across studies, thereby resulting in some heterogeneity across studies. The meta-analysis also did not evaluate the relationship of Lp(a) with the progression or rupture of AAA. In terms of Lp(a) biology, it is well appreciated that Lp(a) is an acute-phase reactant in severely ill patients and levels may rise by 30% to 100% and stay elevated for 3 to 6 months following acute coronary syndromes. 23, 24 The LPA gene contains an interleukin 6 (IL-6) response element, and studies have shown that antibodies to IL-6 reduce Lp(a) levels up to 30%, suggesting Lp(a) elevation in inflammatory conditions. 25 This extent of the difference in Lp(a) levels in AAA cases and controls in this meta-analysis may represent an acute-phase response post hospitalization for AAA in some of the studies. Furthermore, data concerning several factors that can modulate Lp(a) levels, including statins that may raise Lp(a), 26 and niacin 26 that may reduce Lp(a), were not fully reported in the reviewed studies. The potential statin effect is of interest, since a recent meta-analysis-type study showed that statins significantly increase Lp(a) levels on average by 11% but ranging from *10% to 50%. 26 Since many patients with AAA have atherosclerotic risk factors, they are much more likely to be treated with statins compared to controls. Additionally, AAA can directly affect renal function by reducing renal blood flow via its proximity to the renal arteries, and decreased kidney function has been shown to slow the metabolism of Lp(a) resulting in elevated levels. 12 Finally, the potential presence of other cardiovascular disease (CVD) manifestations that are also causally related to Lp(a), such as peripheral arterial disease, 27 may also be associated with or influence AAA formation.
One way to avoid such confounding and address potential reverse causality is to perform genome-wide association or Mendelian randomization studies, where LPA singlenucleotide polymorphisms (SNPs) or kringle IV type 2 isoform repeats can be analyzed for a possible causal relationship with AAA. Since such genetic variables cannot be altered after birth, they effectively rule out reverse causality, that is, the disease or the acute-phase response being responsible for elevated Lp(a). Such a study was performed consisting of 35 case-control series that included 4,572 patients with AAA showing that an LPA score, consisting of 2 major SNPs associated with elevated Lp(a) levels, had an odds ratio (OR; 95% confidence interval [CI]) for AAA of 1.23 (1.11-1.36; P ¼ 6.0 Â 10 -5 ). 28 However, after exclusion of patients with concomitant coronary artery disease, the effect estimates for an LPA score were no longer significant (OR: 1.11; P ¼ . 16 ). This suggests that AAA may be present with other CVD manifestations, and it may be difficult to tease out the causality of Lp(a) for AAA versus the presence of other CVD manifestations. Additional genome-wide association studies in large number of patients may also be useful in further understanding the causal role of Lp(a) in AAA.
Despite 31 and may be a therapeutic option to delay, or even obviate, the need for surgery/intravascular intervention.
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